This paper describes a new indicator of research impact or influence, namely the research experience of health advisory committee members in 21 European countries, and how this relates to the burden of disease in those countries. Attention is confined to five noncommunicable diseases (NCDs): Cancer, cardiovascular diseases, diabetes, mental disorders, and chronic respiratory diseases, and the 5 years 2009-2013. In 2010, these five disease groups accounted for 57% of the disease burden in Europe as measured by Disability-Adjusted Life Years. The file of advisers' research papers contained 12,854 biomedical articles and reviews in the Web of Science, of which 5713 were concerned with one or more of the five NCDs. This output was compared with the relative disease burden in the countries concerned, and with the burden from different manifestations of these diseases such as cancer sites and alcoholism and dementia among mental disorders. such as alcoholism and dementia. The extent of other European countries' contributions to the advisers' research portfolios was also determined; it was higher than expected.
INTRODUCTION
There is a surprisingly large literature on the way medical research can be used, or better used, by policy-makers, which has expanded rapidly since 2004. Despite this, there appears to remain a gap between the world of research and the world of health policy that has been frequently observed, and lamented. [1] [2] [3] [4] [5] [6] Civil servants, who are in many ways the customers for health research, have difficulty in communicating effectively with the research community. [7] [8] [9] A survey of the situation in Europe with regard to health services research in 2009-2010 revealed a remarkably varied picture and poor use of such research by policy-makers, except with regard to new drugs. [10] One disease area in which public and patient advocacy has, however, seen a remarkable influence on both research and policy has been HIV/AIDS, and there may be lessons that can be applied also to cancer treatment. [11] The role of advisory committees is clearly important, and members' views play a big part in the approval process for new drugs and medical devices by the US Food and Drug Administration. [12] In Germany, advisory committees decide on a policy for medical research involving animals, but since the scientists out-number the animal welfare representatives, the committees have not been able to strike a fair balance between conflicting objectives. [13] However, there seems to have been little other study on the role of health department advisory committees in guiding the policies of their departments, or of whether their research experience plays a role in the allocation of resources in health care in their countries. It would be expected that experts in particular fields would argue for greater priority for patients in their specialty and that they would reinforce the messages disseminated by patient groups. However, we found no evidence on how this process might be occurring.
This project was part of an investigation for the European Union (EU) of the research activities in Europe on five noncommunicable diseases (NCDs): Cancer, cardiovascular diseases (including stroke), diabetes, mental disorders, and respiratory diseases. All NCDs together accounted for some 86% of the disease burden in Europe in 2010, according to the recently-published Global Burden of Disease compilation. [14] This is measured in Disability-Adjusted Life Years (DALYs), which take into account both early deaths and the impairment of life for those living with a disability. The five NCD studies here were responsible for 57% of the European total disease burden: Cardiovascular diseases 19.5%, cancer 17.2%, mental disorders 13.2%, respiratory diseases 4.7%, and diabetes 2.5%, though there were considerable variations from country to country, especially in cardiovascular diseases and diabetes.
The investigation aimed to map the outputs of papers (articles and reviews covered in the Web of Science [WoS] for the 12 years, 2002-2013) , their funding sources, and their impacts. We created five large files with papers in each NCD: Cancer 282,055 papers; cardiovascular diseases 211,507 papers; diabetes 40,550 papers; mental disorders 138,666 papers; and respiratory diseases 18,822 papers. There are some conventional measures of research impact, such as citation scores, [15] [16] [17] recommendations by the F1000 group of expert reviewers [18, 19] and percentages of reviews, [20] and we used some of these, but we wanted to explore other indicators to show the influence of the papers on society and on decision-makers in the Member States.
Two useful indicators are the extent to which papers from a country are cited on clinical guidelines [21] [22] [23] [24] and are reported in the mass media. [25, 26] These are good measures of the utility of the research being undertaken, because the objective of the medical research is to provide information that will enable better treatment of patients, and at least as important, to prevent illness in the first place. (This often involves social interventions, which is why we took papers from both the Science Citation Index Expanded and the Social Sciences Citation Index.) The production and use of clinical guidelines have expanded rapidly since 2008 [ Figure 1 ], and particularly in continental Europe (including Iceland and Ireland). In 1995-2007, these 30 countries (the 28 Member States of the EU, plus Iceland, Norway, and Switzerland, but minus the UK) accounted for 124 of 391 papers (32%) but in 2008-2015, for 203 of 512 papers (40%). The analysis of the evidence base of these European clinical guidelines will be presented in separate papers.
The second indicator is the amount of coverage of different medical research papers in newspaper stories in the European countries. Although newspaper print circulations have declined in many countries, they are still very influential as most papers have developed an online presence and can be read on tablets and iPads. They are seen by ministers who set policy, their senior advisers, medical personnel, researchers, and the general public. We recruited a number of research assistants from nearly 20 European countries who could read the stories in the different languages and compile databases of them and the research papers that they cited. This work will also be presented in a separate paper.
A third indicator, the subject of this paper, is the cross-country influence on the knowledge base of healthcare policy advisers in the individual member states. (We originally set out to examine the references on government policy documents, but found that, since they were intended to be read by the general public, they contained pretty pictures rather than scientific references.) We asked our European research assistants to look for and download from the web lists of members of health advisory committees, together with their affiliations and cities. These were to be limited to members during the 5-year period, 2009-2013. We then attempted to list the medical research papers that they had written during these 5 years (articles and reviews in the WoS) so as to create a composite database that could be analyzed, in particular, to show the extent to which these papers were co-authored with researchers from other European countries, and other parameters.
METHODOLOGY
European health departments have a wide variety of advisory committees, and the membership also varies: Some countries depend mainly on health service administrators and experienced officials while others recruit academics. Particularly in Austria and Germany, most members have the title "Professor Doctor" and sometimes "Professor Doctor Doctor" if they also have a Ph.D., and work at universities. Some of the advisory committees have a wide remit, whereas others are concerned just with a particular disease or health problem, and many of these are not relevant to our study of NCDs. For example, the UK Department of Health has no fewer than 33 Advisory Groups, but only one (on obesity) is relevant to our project, plus one on the end of life, now disbanded. These two groups had 47 members, but only 25 of them published any research papers.
Our research assistants collected together the names of all the health advisory committee members in their countries. However, we found that the names were sometimes listed surname first and sometimes given name (s) first; they all had to be manipulated so that the names were in the format: Verne, J which is the preferred format for use in the WoS. Furthermore, any letters with diacritical marks (e.g., accents, cedillas, umlauts) needed to be replaced with ordinary roman letters in both the names and the city names. Some of the latter also needed to be changed as they were usually given in the original form, for example, Milano, München, whereas the WoS only uses the Standard English "translations," i.e. Milan and Munich. The names and city names were then concatenated to a simple WoS search statement such as: (CI = Leipzig AND AU = (Brahler, E OR Hegerl, U)) and these were, in turn, concatenated into complex search strategies, typically with up to about 20 search statements.
These were then run against the WoS for the years 2009-2013, and articles and reviews were identified. However, we found that some of the names also had homonyms working in the same cities but on entirely different subjects such as astronomy, ecology, or physics. We therefore used the WoS facility to identify the subject areas of the papers and removed any in these other fields, and ones in areas of medicine with which our project was not concerned, such as gynecology and infectious diseases. This substantially reduced the numbers of papers whose details had to be downloaded to text files. These were then opened by means of a special Excel macro, written by Philip Roe of Evaluametrics Ltd., and selected contents written to an Excel spreadsheet with the following columns [ Table 1 ].
This standard format allowed the committee members' papers from many different countries to be combined in a single Excel spreadsheet for analysis.
The next step was to check that all the papers were relevant to clinical medicine or biomedical research. The source was parsed to isolate the journal name, and this was then looked up electronically in a large thesaurus of journal names that had previously been categorized into one of some dozen major fields such as chemistry, mathematics, and physics (as well as biomedical research and clinical medicine, the two of interest). Papers in any other field were set aside, and if the fields were remote from medicine, the titles were inspected to check if they were relevant. The objective was to narrow the list of papers by the named committee members (and possibly their homonyms) to those that could potentially be relevant to the five NCDs. The next step in the analysis was to parse the address field, which in the WoS includes all listed addresses, by means of another special macro, again written by Philip Roe, that determined the fractional count of each country on each paper (A paper with one French address and two German ones would be classed as 0.33 for France and 0.67 for Germany.) Papers by Austrian committee members, for example, would be expected all to have at least one Austrian address, but we wanted to know which other countries were contributing to this body of research.
We were not able to find lists of committee members for all the 31 European countries, and some did not appear to have them, so the analysis was confined to 21 countries out of the 31 [ Table 2 ].
We also wanted to see what level of research formed the background of the advisory committee members. This is a decimal number between 1.0 (clinical observation) and 4.0 (basic research) and is based on whether the papers have "clinical" or "basic" words in their titles. [27] It can be applied to the individual papers forming a country group (RL p), or to all the papers in a given journal in which the papers of interest have been published (RL j). The titles of the papers in the spreadsheet were then parsed by yet another macro to show which were "basic," which were "clinical," and which were "both."
The next piece of analysis was more complex, and involved a comparison of the papers in the combined spreadsheet with the ones in the five NCD files referred to earlier. We assumed that the advisory committee papers would have had an address in Europe, even though a few committee members had addresses in another EU Member State, and performed a look-up function so as to identify which papers were in cancer, diabetes, etc. This would allow us to see the balance of the expertise available to the Member State governments. The look-up not only provided information on which papers were in each of the five NCDs, but also the sub-fields within them. These were of two kinds: Applications or manifestations, and types of research. Applications are the individual diseases or disorders, for example, breast or lung cancer, or alcoholism or depression among mental disorders. Types of research include drug therapy, epidemiology, genetics and surgery; they vary according to the NCD as not all would be relevant. In this study, only the types of research in cancer were analyzed. Because some of the members' papers were in medical fields, but not those of the five NCDs, we used as a denominator the sum of the numbers of papers in any of the five so that the balance of expertise within the group of five NCDs could be seen.
The numbers of papers from committee members of each European country varied greatly, and did not necessarily correlate with the amount of research undertaken by the country, or its size or wealth. Thus, Germany had approximately 2000 papers but the UK only about 400. For some countries, it was worthwhile to carry out quite a full analysis of the papers forming its advisory committees' portfolios, but for others the analysis was much simpler -Luxembourg, for example, had only four papers, but all were co-authored internationally. Hungary had five specialist committees whose members came from the particular voluntary organizations for the five NCDs.
RESULTS: OVERALL AND MEASURES OF CO-AUTHORSHIP
The file of papers by the advisory committee members comprised 12,854 articles and reviews, and the distribution by country is shown in Table 3 . The first result is that for most countries (all except for Germany, Spain, the UK, and Finland) the contribution from other European countries is greater than from the rest of the world, whereas typically Europe publishes between 35% and 45% of the world total in most biomedical fields. So one might expect that the Rest of the World would have contributed about half as much again as Europe. Even in Finland, the most extreme case, the ratio is <1.32. Hence, we may conclude that the health committee advisers are better connected to colleagues in Europe (and are therefore benefiting from their expertise) than to those from elsewhere. Overall, "other European countries" contributed 1801 papers to the committee members' outputs compared with "rest of the world" tally of 1017 papers, both on a fractional-count basis.
The papers were fairly clinical, and the mean research level (RL) did not vary greatly between subject areas (the five NCDs) or between countries. The results are shown in Figure 2 , both for the five NCDs and for eight countries for which there were 700 papers or more in total. These results were just for those papers in the five NCDs, that is 5713 papers out of 12,854, or 44%. The papers had a RL averaging 1.49 which was invariably lower (i.e., more clinical) than the average for the journals in which they were published (1.74). Cancer and diabetes research were the most basic, as was that of the advisers in Italy, Spain, Hungary, and the Czech Republic.
We next examined how well the five NCDs were represented among these advisers' portfolios. The papers in the file were all matched against the NCD output files, and the numbers in each of the five NCDs are shown in Table 4 , where they are compared with overall European research outputs and the European disease burden from the five NCDs.
It appears from Table 4 that there is less research experience than would be merited in cardiovascular and respiratory diseases and as a corollary, more than proportionate in diabetes and cancer. However, this is for Europe as a whole, and the situation is perhaps different for individual countries. It is only worth performing this analysis for countries with a large number of papers, and we have limited it to countries with at least 700 papers, i.e., the top eight in Table 3 .
The table generally confirms the findings for Europe mentioned above, but there are some exceptions. In diabetes Germany is under-represented. In oncology the Netherlands is; on the other hand, it is over-represented in respiratory diseases. Italy is under-represented in mental disorders, as is the Netherlands, but Hungary is over-represented here.
RESULTS FOR CANCER
The numbers of papers are great enough to allow an analysis of the main cancer sites (manifestations) and types of research. We confined the analysis to the eight countries in Table 5 , to six leading cancer sites: colorectal (COL), lung (LUN), breast (MAM), pancreas (PAN), prostate (PRO) and stomach (STO); to three treatment methods: chemotherapy (CHEM), radiotherapy (RADI) and surgery (SURG); and to two other research types, genetics (GENE) and pathology (PATH). Figure 3 compares the disease burden from the individual cancers with the output of research by the advisers, relative to all cancers, and Table 6 shows the analysis of the outputs of the advisers in the eight countries.
This shows the frequently-found imbalance for lung and breast cancers. The former is under-researched and the latter over-researched, in relation to all cancers, but also pancreatic cancer does not get as much attention from the advisers as it would appear to merit whereas prostate cancer receives proportionately more attention.
There is much less variation in the disease burden from these six cancers across Europe, except that prostate cancer is relatively less of a burden in the three Eastern European countries (Poland and Hungary, and to a less extent the Czech Republic), perhaps because the life expectancy of their men is lower, so the lack of expertise among advisory committee members is understandable. Hungary and Poland suffer relatively more from lung cancer, and their advisers' expertise in the subject is clearly extensive and relevant. There are some surprising differences in expertise in different research types, with Germany and Italy strong in surgery, but the Netherlands rather weak in several treatment types.
RESULTS FOR MENTAL DISORDERS
The second sub-field analysis that we conducted was of different manifestations of mental disorders. These differ greatly from one another, and there is likely to be less carry-across of expertise in the different manifestations than for some other disease areas. Figure 4 shows the percentages of DALYs and of research for six different mental disorders, both as fractions of the total due to mental disorders. These are an addiction (ADD), alcoholism (ALC), Alzheimer's disease and other dementias (ALZ), anxiety and panic disorders (ANX), unipolar depression (DEP) and schizophrenia (SCH). The addictions, alcoholism, anxiety disorders, and depression appear to be receiving less attention than they need, but schizophrenia has much research experience among the advisers compared with its burden.
The numbers of papers are much smaller than for cancer, and some countries in Table 7 appear to have unbalanced advice from their health committee advisers if it is based on their research experience. The dementias are well researched by the advisers in Spain, Italy and the Czech Republic, and schizophrenia in Austria. However in some countries, there is almost no research experience in mental disorders among its advisers, notably Italy (except for dementia).
RESULTS FOR CARDIOVASCULAR DISEASE
The third analysis was of cardiovascular diseases, including cerebrovascular disease (stroke). The definitions that we used to create sub-fields of CARDI do not correspond accurately to the data for disease burden, but it is instructive first to see how the percentages of papers from advisers compare with the overall disease burden from cardiovascular diseases, which varies much more than that from cancer. The data are in Table 5 .
The three eastern European "accession" countries that were socialist until 1989 and joined the EU in May 2004 clearly have much higher levels of cardiovascular disease than the others, but the correlation between DALYs and papers shown in Table 5 is almost nil (r 2 = 0.02). The Netherlands is the only one of the eight countries that have more research experience among its health advisers than cardiovascular disease would warrant and contrasts with Germany and Hungary, which have less than half as much as would be proportionate. Numbers  AT  102  45  143  371  15  411  72  321  361  109  CZ  185  40  101  288  6  758  79  313  583  110  DE  174  22  284  587  15  4630  638  3169  4268  1068  ES  116  36  91  263  39  1783  395  1644  1934  526  HU  165  68  185  293  42  994  106  329  661  155  IT  94  22  33  245  8  3008  516  2109  3010  678  NL  241  136  144  149  108  608  84  725  829 Table 8 shows the distribution of papers between six leading subject areas, with 150 or more papers from all the countries. The subjects are arterial disease including atherosclerosis and aortic aneurysms (ART); cerebrovascular disease (stroke, CER); ischemic heart disease including acute myocardial infarction (ISC); arrhythmias, including atrial fibrillation (ARR); hypertension (HYP); and heart failure (FAI).
The distribution of cardiac expertise is very unbalanced, with Austria showing to advantage in hypertension (HYP) and cerebrovascular disease (CER) but not in heart failure (FAI), and Italy relatively very strong in arterial disease (ART) but weak elsewhere.
RESULTS FOR RESPIRATORY DISEASE
The final analysis is of two respiratory diseases, asthma (AST), and chronic obstructive pulmonary disease (COPD) (COP). These account for 1.1% and 2.9% of all European DALYs, so the latter is much more serious, but receives less research attention. [29] There are also fewer research papers on COPD from the advisers (107) than ones on asthma (131). In Table 9 , the comparison is with the total numbers of papers from each country in the five NCDs because respiratory medicine is dominated by these two diseases -the main other one being cystic fibrosis, but there are only 12 papers on this disease in the database. There is a relative lack of research expertise in respiratory diseases generally, and particularly in COPD with the conspicuous exceptions of the Netherlands and Spain. Spain has a lower relative disease burden from these two diseases together than any other country in "Western" Europe except for Finland, and this may be as a result of having much expertise in COPD (but not in asthma).
However, the Netherlands is not so well placed and is as high as sixth (out of 31 countries) in its relative burden from the two diseases. Table 2 . ADD=Addiction, ALC=Alcoholism, ALZ=Alzheimer's, ANX=Anxiety, DEP=Depression, SCH=Schizophrenia, MENTH=Mental disorders, DALYs=Disability-adjusted life years 
DISCUSSION AND CONCLUSIONS
In this paper, we have compared the research outputs of members of European countries' health advisory committees with their countries' disease burdens. There is an implicit assumption that there should be a correlation, namely that these advisers should be selected on the basis that their expertise should match the clinical needs of the countries. That means that diseases that cause a relatively greater burden should be matched by the presence of expert advisers who know about these diseases (or mental disorders). This would allow them to argue for better treatment facilities for patients. There is also a parallel assumption that a country's biomedical research portfolio should reflect its disease burden, so that it will be better able to treat patients and to take steps to reduce the diseases' incidence.
However, the inverse may also be the case, i.e., that if a country has invested heavily in research on a particular disease for some years, and has health policy advice stemming from this research, this should have led to an improvement in the situation, with fewer patients and better outcomes. This is a kind of "holy grail" of medical research: More research leads to better health. Of course, the links are far more complex than that, and many steps are needed to translate research findings, usually from many different sources, into better treatment for patients and for less illness [ Figure 5 ].
This diagram [30] shows how central "Government policy" is to the provision of better health, and how dependent it is on many different sources. (omits the role of advisory committees, but governments have been known to reject the advice of experts or even to dismiss them if their views are unpalatable. [31] Better health is not just a matter of better clinical care, but economic policy plays a major role too, particularly in the reduction of communicable, maternal, and nutritional diseases through better housing, clean air and water, and good food supplies. In Europe, most of these are available to most of the population (but by no means all) and attention is increasingly being paid to the improvement of "lifestyle choices," such as the reduction of smoking, more exercise and better food choices. Health advisory committees can assist with the selection of government policies that affect all of these though until recently there has been a success on a wide scale only for the discouragement of smoking. This may reflect the focus of advisory committees more on the physical than the social determinants of disease. [30] This study is a preliminary attempt to see how research can feed through into governmental health policy through the members of health advisory committees. It suffers from several limitations. The list of these committees is not complete, and it only gives members at a particular point in time. We have not been able to investigate the personal characteristics of the members, such as age, sex, and background (research or clinical practice or both), because there were so many of them (over 1400). More importantly, we do not know whether the advice that they tendered was actually accepted by their governments and translated into new or revised policies. However, we did observe that the papers in our database were predominantly clinical and biological science rather than social science, and this may be a lacuna that governments need to address if they are to be successful in changing people's habits and lifestyle choices.
